00817nas a2200289   4500000000100000008004100001100001300042700001600055700001500071700001500086700001500101700001600116700001600132700001200148700001200160700001200172700001400184700001400198700003600212700001000248700001200258700001400270245020300284250002100487300001200508490000700520       2013                            d1 aJiang L.1 aHopewell J.1 aCollins R.1 aBaigent C.1 aLandray M.1 aPedersen T.1 aArmitage J.1 aChen Y.1 aChen Z.1 aHill M.1 aHaynes R.1 aHaynes R.1 aHPS2-THRIVE Collaborative Group1 aJ. Li1 aF. Chen1 aS. Parish00aHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment  a26 February 2013  a1279-910 v34